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Objective. To estimate HPV prevalence among pregnant women from Ribeir˜ ao Preto, Brazil, and the possible inﬂuence of HIV-
1 infection on this prevalence. Methods. A cross-sectional study with 44 HIV-positive and 53 HIV-negative pregnant women was
conducted.Cervicovaginalspecimenswereobtainedfromallwomenduringgynecologic exam.HPVDNA,lowandhighriskHPV
types, was detected using conventional PCR. Statistical analysis used Student’s t-test, Mann-Whitney test, Fischer’s Exact test, and
prevalence ratios with 95% conﬁdence interval. Results. HIV-positive pregnant women had higher proportion of HPV infection
than HIV-negative pregnant women (79.5% versus 58.5%; P<. 05). HPV positivity prevalence ratio for HIV-positive women was
1.36 (95% CI 1.04–1.8; P = .03). There was signiﬁcant association between HIV viral load levels and HPV positivity (P<. 05).
Conclusions. Our results demonstrate higher HPV positivity in HIV-infected pregnant women. Higher values of HIV viral load
were associated with HPV positivity.
Copyright © 2009 Emilia Moreira Jalil et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The human papillomavirus (HPV) infection is the most
common sexually transmitted disease (STD) worldwide,
representing a signiﬁcant health problem due to its high
prevalence and transmissibility. It is estimated that 75
percent of the sexually active population has been exposed
to HPV [1]. Prevalence estimates vary according to the diag-
nostic method and the population examined, with higher
rates being observed in studies using molecular biology
and including young women with high-risk sexual behavior
[2].
Women living with human immunodeﬁciency virus
(HIV) are particularly susceptible to HPV infection with
elevatedprevalencerates[3]andhigherHPVpositivitywhen
compared with women without HIV infection [4]. They also
present more commonly persistent infections and cervical
intraepithelial lesions [5]. The HPV positivity depends on
plasma HIV viral load and CD4 T cell count, mainly below
200cells/mm3 [6, 7].
It was hypothesized that pregnancy might interfere with
HPV infection due to physiological immune modiﬁcations
[8]. The most feared consequence of HPV infection during
pregnancy is the occurrence of juvenile laryngeal papillo-
matosis, which is rare but is associated with signiﬁcant
morbidity and linked to mother-child transmission of the
virus [9]. HPV prevalence rates vary widely in pregnant
women, ranging from 5.5% to 65% [10].
Few studies have evaluated the interaction between
pregnancy and HIV/HPV coinfection. Bolen et al. [11]2 Obstetrics and Gynecology International
Table 1: Characteristics of participants by HPV and HIV serostatus.
Characteristics HPV-positive HPV-negative P-value
n = 66 n = 31
Number and percentage of HIV-positive 35/66 (53.03%) 9/31 (29.03%) <.05
Number and percentage of HIV-negative 31/66 (46.97%) 22/31 (70.97%)
Mean age (SD) of HIV-positive 27.2 (6.19) 28.2 (4.81) .65
Mean age (SD) of HIV-negative 23.97 (6.16) 23.23 (5.67) .86
Mean CD4 T cell count (SD) in HIV-positive (cells/mm3) 419.2 (240.2) 582.4 (191.8) .067
Mean (SD) viral load in HIV-positive (copies/mL) 31,628 (86,848) 1,610 (3,151) <.05
Mean number (SD) of previous pregnancies in HIV-positive 3.9 (2.2) 3.1 (1.3) .38
Mean number (SD) of previous pregnancies in HIV-negative 2.4 (1.7) 1.9 (1.2) .21
Mean age (SD) at ﬁrst sexual intercourse in HIV-positive 15.8 (2.55) 15.7 (2.12) .92
Mean age (SD) at ﬁrst sexual intercourse in HIV-negative 16.2 (2.46) 16.6 (3.47) .78
Marital status in HIV-positive
Married/cohabiting 24 9 .08
Single/divorced/widowed 11 0
Marital status in HIV-negative
Married/cohabiting 20 16 .57
Single/divorced/widowed 11 6
Lifetime number of sexual partners in HIV-positive
≤52 2 8 . 4 6
>51 2 2
Lifetime number of sexual partners in HIV-negative
≤52 9 1 9 . 6 3
>52 3
Number and percentage of previous STD in HIV-positive 14/35 (40%) 1/9 (11.1%) .13
Percentage of previous STD in HIV-negative 4/31 (12.9%) 0/22 (0%) .13
Percentage of past/current smokers in HIV-positive 13/35 (37.1%) 1/9 (11.1%) .23
Percentage of past/current smokers in HIV-negative 10/31 (32.3%) 4/22 (18.2%) .35
SD: Standard deviation;
STD: Sexually transmitted diseases.
identiﬁed an overall HPV prevalence of 35.5% among HIV-
positive pregnant Thai women. Similar rates were found in
a North-American cohort of HIV-infected pregnant women
[12]. Taking into account the scarce data available about
this theme and the relevance of HPV infection for public
health, the objective of the present study was to estimate
HPV prevalence among pregnant women from Ribeir˜ ao
Preto, Brazil, and to identify the possible inﬂuence of HIV-1
infection on this prevalence.
2.MaterialsandMethods
A cross-sectional study was conducted from May 2006 to
February 2007 on 44 HIV-positive pregnant women from
thePrenatalOutpatientClinicoftheInfectiousDiseasesUnit
andon53HIV-negativepregnantwomenfromtheLow-Risk
Prenatal Outpatient Clinic of the Obstetrics and Gynecology
Department of the University Hospital, Medical School of
Ribeir˜ ao Preto, University of S˜ ao Paulo. This service is a
tertiary hospital with a large catchment population mainly
of middle and low socioeconomic status. Women aged 15–
40 years and with more than 21 weeks of gestation were
selected for both groups. HIV-infected pregnant women had
a previous or current diagnosis of the infection and no other
disease, whereas non-HIV-infected women had no diseases
and were considered normal from a clinical and serologic
viewpoint.
The study protocol was approved by the Ethics Review
Board of the hospital, and all women gave written informed
consent to participate. A structured questionnaire was
applied by the researchers in a personal interview to obtain
sociodemographic characteristics, medical, reproductive,
contraceptive, and sexual history, and laboratory data. All
women had a gynecologic examination that included a
Papanicolaou smear and the collection of cervicovaginal
specimenswhichwerestoredin5mLofsterilesalinesolution
on the same day at −80◦ until processing. DNA extraction
was performed as previously described [13]. We included
both low and high risk HPV types.
The extracted preparations were assessed by the poly-
merase chain reaction (PCR) using β-globin primers PCO3
and PCO4 [14] to conﬁrm the presence of an adequate
quality of DNA and the absence of inhibitors. HPV DNA
was detected by conventional PCR with consensus primersObstetrics and Gynecology International 3
GP5+/GP6+, which amplify a 150 base pair (bp) fragment
from the L1 open reading frame of a broad spectrum of
mucosotropic HPV types [15]. PCR was carried out in a
25μL reaction mix containing 5% glycerol, 3.0μMM g C l 2,
20mM of each deoxynucleoside triphosphate, 0.6mM of
each primer (Fermentas, Canada), 1× buﬀer (200mM
Tris-HCl, pH 8.4, and 500mM KCl), 1.25 units of DNA
polymerase (Invitrogen, USA), and 1μL of extracted DNA.
To standardize the PCR protocol, suspensions of HeLa and
SiHa cells naturally infected with HPV-18 and HPV-16,
respectively, were used as positive controls. Distilled water
was used as the negative control. The thermal cycling con-
ditions were denaturation of DNA template and activation
of DNA polymerase at 94◦C for 7 minutes, 37 cycles at 94◦C
for 30 seconds, at 45◦C for 45 seconds, and at 72◦Cf o r1
m i n u t e ,a n daﬁ n a le x t e n s i o na t7 2 ◦C for 10 minutes. PCR
products were run on a 10% nondenaturing polyacrylamide
gel, followed by silver staining as described by Sanguinetti et
al.[16],andclassiﬁedasHPVpositiveifabandof150bpwas
identiﬁed when compared to a 100bp ladder marker.
A data bank was generated and analyzed in GraphPad
Prism, version 4.00. Prevalence ratios (PRs) for variables
of interest with 95% conﬁdence intervals (95% CI) were
calculated. A two-tailed P-value of <.05 was regarded as
signiﬁcant; for statistical analysis, Student’s t-test, Mann-
Whitney test, and Fischer’s Exact test were employed.
3. Results
Table 1 shows the characteristics of participants by HPV and
HIVstatus.HIV-positivepregnantwomenhadasigniﬁcantly
higher proportion of HPV infection than HIV-negative
pregnant women (79.5% versus 58.5%; P<. 05). HIV-
positive serostatus was a risk factor for HPV positivity (PR
1.36; 95% IC 1.04–1.8; P = .03).
CD4 T cell count above 500 cells/mm3 and HIV RNA
viral load below 1000copies/mL were identiﬁed in 45%
and 50% of HIV-positive pregnant women, respectively.
All HIV-infected pregnant women with less than 200 CD4
T cells/mm3 or more than 10 000 HIV RNA copies/mL
were HPV DNA positive. In the global context, there was
signiﬁcant association between HPV positivity and viral load
(P<. 05), but there was no clear association between HPV
positivity and CD4 T cell count (P = .067), as showed in
Table 1. Other characteristics were not signiﬁcantly diﬀerent
according to HPV status.
4. Discussion
The prevalence of HPV infection detected in the present
study was high among both HIV-positive and −negative
pregnantwomen(79.5%and58.5%,resp.),withasigniﬁcant
diﬀerence between the two groups. Few studies have been
conducted on HIV-positive pregnant women. Minkoﬀ et al.
[12] suggested that HPV infection was not aﬀected by
pregnancy status among HIV-infected women. Our results
are similar to ﬁndings reported in other studies [4, 6, 17],
which identiﬁed higher HPV DNA positivity among HIV-
infected nonpregnant women.
Higher viral load levels were associated with HPV
positivity in the present study, which is in accordance with
earlier studies [4, 8, 11]. Although we have not observed
signiﬁcant association between CD4 T cell count and HPV
positivity, probably due to our limited sample of cases, a
trend to this association is already possible to identify.
HPV DNA positivity was also high among HIV-un-
infected pregnant women. Oliveira et al. [18] found similar
HPV positivity rates in Brazilian HIV-negative women. This
ﬁnding could also be due to the high percentage of young
women, aged less than 25 years in this group, since age is
one of the main risk factors for HPV infection [2]. In the
same region of this study, Santos [19] found almost 52% of
HPV positivity in pregnant teenagers. One weakness of our
method might be that due to the absence of a nonpregnant
women group, the possible immunosuppressive eﬀect of
gestation increasing the HPV rates cannot be assumed based
on our study. A comparison with nonpregnant women could
help elucidate this ﬁnding. In this context, another study
conducted at our institution detected a 30% rate of HPV
infection in HIV-uninfected women [20].
Even though the limited sample of cases and the target
population, based on a tertiary health service, may restrict
the generalization of our data, important results have already
been demonstrated in the present study. According to our
data, there is a signiﬁcant association between HPV DNA
positivity and HIV serostatus. Higher HIV viral load seems
to be a major factor associated with HPV-HIV interaction.
Short- and long-term active surveillance is needed to issue a
deﬁnitive statement regarding the clinical signiﬁcance of this
ﬁnding during pregnancy for HIV infected women.
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